hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 06:09:11 - browse：71665

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Lindsay Lohan welcomes 1st child with husband Bader Shammas

knowledge

WSS

The kidney, in all its complexity, is captured in a new atlas

WHO recommends second malaria vaccine

Setback for rare diseases as Taysha Gene Therapies pulls back

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Resistance to cancer drugs: A new genetic explanation

Will an HIV vaccine ever be a reality?

knowledge

hotspot

knowledge

Alkermes shareholders re

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Hepatitis C has a cure — but many Americans still lack access to it

Setback for rare diseases as Taysha Gene Therapies pulls back

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What we owe ALS patients — and why one company fell short

New air purifier tech could be key to improving indoor air quality

The United States is paying nearly triple for new Covid vaccines

What does generative AI mean for health care? We asked experts

Man who had jail sentence commuted by Trump arrested again

knowledge

States increasingly look to regulate hospital facility fees

How dance can help health care workers heal from trauma

Congress extends some pandemic preparedness programs

The biotech scorecard for Q4: 16 stock

Stanford updates investigation of president’s past research

Resistance to cancer drugs: A new genetic explanation

hotspot

knowledge

focus

hotspot